drugset / Trial / NCT02358265

Chronic Urticaria - Long Term Assessment of Effects of Rupatadine

NCT02358265

Phase 3 Terminated 192 enrolled Charite University, Berlin, Germany
RandomizedParallel-groupDouble-blindTreatment

Summary

To compare CSU disease activity at the end of the follow up phase between patients that had been treated daily continuously vs. on-demand in the treatment phase

Timeline

Start
2014-12
Primary completion
2017-11-20
Completion
2018-06-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rupatadine Small molecule 10 mg Oral
Comparator Rupatadine Small molecule 20 mg Oral

Indications